Alzheimer disease (AD) is a neurodegenerative disorder characterized by the accumulation of amyloid-β (Aβ) plaques and neurofibrillary tangles of hyperphosphorylated tau in the brain.1 These neuropathologic changes are believed to take part in a cascade of events that result in a characteristic neurodegeneration pattern followed by progressive cognitive impairment.2 Tracking neurodegenerative changes in vivo is important for monitoring AD progression. This evidence concerns the gene MAPT and Cognitive impairment.